1. Afilalo J, Duque G, Steele R, Jukema JW, de Craen AJ, Eisenberg MJ. Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis. J Am Coll Cardiol 2008 Jan 1;51(1):37-45.

2. Anderson TJ, Gregoire J, Hegele RA, Couture P, Mancini J, McPherson R, et al. 2012 Update of The Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Canadian Journal of Cardiology 2013;29:151-67

3. Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol 2012 May;6(3):208-15.

4. de Longeril M, Salen P, Abramson J, Dodin S, et al. . Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-jupiter controversy: A critical reappraisal. Archives of Internal Medicine 2010 Jun 28;170(12):1032-6.

5. Diabetes Care Program of Nova Scotia DHW SEAscape Database, June 2011

6. GISSI-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet 2008;372:1231-39.

7. Glynn RJ, Koenig W, Nordestgaard BG, Shepherd J, Ridker PM. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: Exploratory analysis of a randomized trial. Ann Intern Med 2010; 152: 488-96.

8. Hanlon JT, Schmader KE, Samsa GP, et al. A method for assessing drug therapy appropriateness. J Clin Epidemiol 1992;45: 1045-1051.

9. Holmes HM, Hayley DC, Alexander GC, Sachs GA. Reconsidering medication appropriateness for patients late in life. Arch Intern Med 2006; 166: 605-9

10. Kjekshus J, Apatrei E, Barrios V, et al, for the CORONA group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-61.

11. Lee DH, Buth KJ, Martin BJ, Yip AM, Hirsch GM. Frail patients are at increased risk for mortality and prolonged institutional care after cardiac surgery. Circulation. 2010;121:973-978

12. Lipid Lowering in Primary Prevention: a calculated risk, Dalhousie CME Academic Detailing Service, February 2013,

13. Mancini GB, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. Can J Cardiol 2011 Sep;27(5):635-62

14. Moorhouse P, Mallery LH. Palliative and therapeutic harmonization: a model for appropriate decision-making in frail older adults. J Am Geriatr Soc 2012, Dec;60(12):2326–2332.

15. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002 Jul 6;360(9326):7-22.

16. Mutasingwa DR, Ge H, Upshur RE. How applicable are clinical practice guidelines to elderly patients with comorbidities? Can Fam Physician 2011; 57: e253-62.

17. Richardson K, Schoen M, French B, Umscheid CA, Mitchell MD, Arnold SE, et al. Statins and cognitive function: a systematic review. Ann. Intern. Med. 2013 Nov 19;159(10):688–97.

18. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr., Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008 Nov 20;359(21):2195-207.

19. Rockwood K, Song X, MacKnight C, et al.  A global clinical measure of fitness and frailty in elderly people. CMAJ 2005, Aug 30;173(5):489–495.

20. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002 Nov 23;360(9346):1623-30.

21. Tinetti ME, Bogardus ST Jr, Agostini JV. Potential pitfalls of disease-specific guidelines for patients with multiple conditions. N Engl J Med 2004;351: 2870-74.

22. Yusuf S, Lonn E, Bosch J. Lipid lowering for primary prevention. Lancet 2009 Apr 4;373(9670):1152-5.